Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Cerilliant
Citi
Johnson and Johnson
Teva
Moodys
QuintilesIMS
Chubb

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,377,982

« Back to Dashboard

Which drugs does patent 8,377,982 protect, and when does it expire?

Patent 8,377,982 protects ACULAR LS and is included in one NDA.

Protection for ACULAR LS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has four patent family members in three countries.
Summary for Patent: 8,377,982
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s): Muller; Christopher A. (Foothill Ranch, CA), Cheetam; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA)
Assignee: Allergan Sales, LLC (Irvine, CA)
Application Number:13/434,956
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,377,982
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,377,982

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ACULAR LS ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 021528-001 May 30, 2003 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,377,982

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,216,167 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Sign Up
8,541,463 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Sign Up
8,008,338 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Sign Up
8,946,281 Ketorolac tromethamine compositions for treating or preventing ocular pain ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,377,982

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2468664 ➤ Sign Up
Canada 2967362 ➤ Sign Up
European Patent Office 3217937 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2016077726 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Baxter
Colorcon
Citi
Cantor Fitzgerald
Argus Health
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.